---
company: JOHNSON & JOHNSON
ticker: JNJ
form: 8-K
filed: 2026-07-15
accession: 0000200406-26-000146
source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/
---

# Johnson & Johnson (JNJ) earnings release, July 15, 2026

Johnson & Johnson (JNJ) · Form 8-K, Item 2.02 · Filed 2026-07-15 · [SEC filing](https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/)

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

• 2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%*

• 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90

• Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint

• Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA in upper abdominal procedures

New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”

Overall financial results¹

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules²

Excludes the impact of translational currency³

Excludes the net impact of acquisitions and divestitures and translational currency⁴

Excludes intangible amortization expense and special items⁵

Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.⁶

Second-quarter YTD 2026 is estimated as of July 15, 2026

Note: values may have been rounded

Regional sales results¹

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules²

Excludes the impact of translational currency³

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results¹

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules²

Excludes the impact of translational currency³

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Second-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.

MedTech

MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.¹

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures²

Non-GAAP financial measure; excludes the impact of translational currency³

Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17 (Illustrative purposes only)⁴

Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at

Investor News, as well as

Innovative Medicine Newsroom,

MedTech News & Events, and www.factsabouttalc.com.¹

Subsequent to the quarter

Webcast information:... (truncated)iting the

Johnson & Johnson website.

A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an

Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

Note to investors concerning forward-looking statements:

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation.

A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

## Financial statements

### Income Statement (SECOND QUARTER — Condensed consolidated statement of earnings (Unaudited; in Millions Except Per Share Figures))

| | SECOND QUARTER – 2026 – Amount | SECOND QUARTER – 2026 – Amount | SECOND QUARTER – 2026 – Percent to Sales | SECOND QUARTER – 2025 – Amount | SECOND QUARTER – 2025 – Amount | SECOND QUARTER – 2025 – Percent to Sales | SECOND QUARTER – Percent Increase (Decrease) |
|---|---:|---:|---:|---:|---:|---:|---:|
| Sales to customers |  | 25,310 | 100 |  | 23,743 | 100 | 6.6 |
| Cost of products sold | 8,051 |  | 31.8 | 7,628 |  | 32.1 | 5.5 |
| Gross Profit | 17,259 |  | 68.2 | 16,115 |  | 67.9 | 7.1 |
| Selling, marketing and administrative expenses | 6,432 |  | 25.4 | 5,889 |  | 24.8 | 9.2 |
| Research and development expense | 3,653 |  | 14.4 | 3,516 |  | 14.8 | 3.9 |
| Interest (income) expense, net | 62 |  | 0.2 | 48 |  | 0.2 |  |
| Other (income) expense, net | 331 |  | 1.3 | 107 |  | 0.5 |  |
| Restructuring | 34 |  | 0.2 | 64 |  | 0.3 |  |
| Earnings before provision for taxes on income | 6,747 |  | 26.7 | 6,491 |  | 27.3 | 3.9 |
| Provision for taxes on income | 1,213 |  | 4.8 | 954 |  | 4 | 27.1 |
| Net earnings |  | 5,534 | 21.9 |  | 5,537 | 23.3 | -0.1 |
| Net earnings per share (Diluted) | 2.27 |  |  | 2.29 |  |  | -0.9 |
| Average shares outstanding (Diluted) | 2,440.1 |  |  | 2,419.1 |  |  |  |
| Effective tax rate | 18 | % |  | 14.7 | % |  |  |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Earnings before provision for taxes on income |  | 8,660 | 34.2 |  | 8,188 | 34.5 | 5.8 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Net earnings |  | 7,081 | 28 |  | 6,699 | 28.2 | 5.7 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Net earnings per share (Diluted) | 2.9 |  |  | 2.77 |  |  | 4.7 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Effective tax rate | 18.2 | % |  | 18.2 | % |  |  |

### Income Statement (Condensed consolidated statement of earnings (Unaudited; in Millions Except Per Share Figures))

| | SIX MONTHS – 2026 – Amount | SIX MONTHS – 2026 – Amount | SIX MONTHS – 2026 – Percent to Sales | SIX MONTHS – 2025 – Amount | SIX MONTHS – 2025 – Amount | SIX MONTHS – 2025 – Percent to Sales | SIX MONTHS – Percent Increase (Decrease) |
|---|---:|---:|---:|---:|---:|---:|---:|
| Sales to customers |  | 49,372 | 100 |  | 45,636 | 100 | 8.2 |
| Cost of products sold | 16,157 |  | 32.7 | 14,985 |  | 32.8 | 7.8 |
| Gross Profit | 33,215 |  | 67.3 | 30,651 |  | 67.2 | 8.4 |
| Selling, marketing and administrative expenses | 12,466 |  | 25.3 | 11,001 |  | 24.1 | 13.3 |
| Research and development expense | 7,180 |  | 14.5 | 6,741 |  | 14.8 | 6.5 |
| In-process research and development impairments | 36 |  | 0.1 |  |  |  |  |
| Interest (income) expense, net | 105 |  | 0.2 | -80 |  | -0.2 |  |
| Other (income) expense, net | 625 |  | 1.3 | -7,214 |  | -15.8 |  |
| Restructuring | 66 |  | 0.1 | 81 |  | 0.2 |  |
| Earnings before provision for taxes on income | 12,737 |  | 25.8 | 20,122 |  | 44.1 | -36.7 |
| Provision for taxes on income | 1,968 |  | 4 | 3,586 |  | 7.9 | -45.1 |
| Net earnings |  | 10,769 | 21.8 |  | 16,536 | 36.2 | -34.9 |
| Net earnings per share (Diluted) | 4.41 |  |  | 6.82 |  |  | -35.3 |
| Average shares outstanding (Diluted) | 2,443.9 |  |  | 2,423.3 |  |  |  |
| Effective tax rate | 15.5 | % |  | 17.8 | % |  |  |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Earnings before provision for taxes on income |  | 16,481 | 33.4 |  | 16,199 | 35.5 | 1.7 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Net earnings |  | 13,695 | 27.7 |  | 13,405 | 29.4 | 2.2 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Net earnings per share (Diluted) | 5.6 |  |  | 5.53 |  |  | 1.3 |
| Adjusted earnings before provision for taxes and net earnings (1) (A) | Effective tax rate | 16.9 | % |  | 17.2 | % |  |  |

### Income Statement (SECOND QUARTER — Reconciliation of non-GAAP financial measures (Dollars in Millions Except Per Share Data))

| | SECOND QUARTER – 2026 | SECOND QUARTER – 2025 | SIX MONTHS – 2026 | SIX MONTHS – 2025 |
|---|---:|---:|---:|---:|
| Net Earnings, after tax- as reported | 5,534 | 5,537 | 10,769 | 16,536 |
| Pre-tax Adjustments | Litigation related | 267 | 57 | 597 | -6,909 |
| Pre-tax Adjustments | Intangible Asset Amortization expense | 1,245 | 1,267 | 2,492 | 2,387 |
| Pre-tax Adjustments | Restructuring related 1 | 276 | 79 | 338 | 134 |
| Pre-tax Adjustments | Orthopaedics separation related | 258 |  | 377 |  |
| Pre-tax Adjustments | Acquisition, integration and divestiture related | 80 | 246 | 176 | 378 |
| Pre-tax Adjustments | (Gains)/losses on securities | -213 | 21 | -272 | 60 |
| Pre-tax Adjustments | IPR&D impairments |  |  | 36 |  |
| Pre-tax Adjustments | Other |  | 27 |  | 27 |
| Tax Adjustments | Tax impact on special item adjustments 2 | -368 | -321 | -792 | 994 |
| Tax Adjustments | Tax legislation and other tax related | 2 | -214 | -26 | -202 |
| Tax Adjustments | Adjusted Net Earnings, after tax | 7,081 | 6,699 | 13,695 | 13,405 |
| Tax Adjustments | Average shares outstanding (Diluted) | 2,440.1 | 2,419.1 | 2,443.9 | 2,423.3 |
| Tax Adjustments | Adjusted net earnings per share (Diluted) | 2.9 | 2.77 | 5.6 | 5.53 |
| Tax Adjustments | Operational adjusted net earnings per share (Diluted) | 2.86 |  | 5.43 |  |

### Income Statement (Overall financial results ($ in Millions, except EPS))

| | Q2 | Q2 – 2026 | Q2 | Q2 – 2025 | Q2 | Q2 – % Change | Q2 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Reported Sales |  | 25,310 |  | 23,743 |  | 6.6% |  |
| Net Earnings |  | 5,534 |  | 5,537 |  | -0.1% |  |
| EPS (diluted) |  | 2.27 |  | 2.29 |  | -0.9% |  |
| Non-GAAP* ($ in Millions, except EPS) | 2,026 |  | 2,025 |  |  |  | % Change |
| Operational Sales1,2 |  |  |  |  |  |  | 5.6% |
| Adjusted Operational Sales1,3 |  |  |  |  |  |  | 5.7% |
| Adjusted Net Earnings1,4 |  |  | 7,081 |  | 6,699 |  | 5.7% |
| Adjusted EPS (diluted)1,4 |  |  | 2.9 |  | 2.77 |  | 4.7% |
| Free Cash Flow5,6 |  |  | ~$8,700 |  | 6,214 |  |  |

### Income Statement (($ in Billions, except EPS))

| | July 2026 | April 2026 |
|---|---:|---:|
| Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 6.2% – 6.8% / 6.5% | 5.6% – 6.6% / 6.1% |
